Literature DB >> 8927682

Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study.

I Berman1, A Merson, C Sison, E Allan, C Schaefer, M Loberboym, M F Losonczy.   

Abstract

Although there is evidence that some schizophrenia patients may have altered regional cerebral blood flow patterns, few studies have addressed the relationship between cortical activity and changes in psychiatric symptoms following treatment, particularly in the elderly. We took advantage of an existing safety and tolerance study of risperidone in the elderly and examined the possible relationship between changes in psychiatric symptoms following risperidone and changes in relative cortical perfusion in a group of 6 elderly schizophrenia patients. All subjects were at least 65 years old and diagnosed with schizophrenia according to DSM-III-R criteria. The patients were assessed using the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) and Mini-Mental Status Examination (MMSE) and had single photon emission computed tomography (SPECT) studies before and at least 3 weeks after change of their previous neuroleptic to risperidone. The frontal/total cortex and temporal/total cortex counts in the slice ratios, and 99mTechnitium-hexamethylpropylene amine oxime (99mTc-HMPAO) percentage uptake in the whole cortical area in the slice were used for data analysis. With risperidone, patients (age 66-81) scored better on the PANSS, particularly in the positive symptom subtests. The changes in positive symptom scores correlated directly with those in frontal and temporal relative activity and 99mTc-HMPAO percentage uptake in the whole cortical area in the slice. Our findings suggest that the improvement in psychotic symptoms after risperidone is associated with a decrease in frontal and temporal activity and a reduction in 99mTc-HMPAO percentage uptake in the entire cortical area in the slice and agree with data from younger populations. Comparative studies assessing the therapeutic impact of neuroleptics on cortical activity in different age groups could be helpful in examining both the mechanisms of action of various drugs and the links between symptoms and specific brain areas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8927682

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  6 in total

Review 1.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

2.  Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study.

Authors:  M Soyka; W Koch; H J Möller; T Rüther; K Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-18       Impact factor: 5.270

3.  Evaluation of regional cerebral blood flow in fahr disease with schizophrenia-like psychosis: a case report.

Authors:  Masaru Shoyama; Masaru Shouyama; Yuji Kitabata; Tetsuji Kaku; Kazuhiro Shinosaki
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

4.  Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change.

Authors:  E T C Ngan; C J Lane; T J Ruth; P F Liddle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

5.  Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis.

Authors:  Ulysses S Torres; Eduardo Portela-Oliveira; Stefan Borgwardt; Geraldo F Busatto
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

6.  A review of SPECT studies in psychiatry in China.

Authors:  Shenxun Shi; Liang Shu
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.